238 related articles for article (PubMed ID: 26419724)
1. Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistance.
Kesarwani M; Huber E; Kincaid Z; Evelyn CR; Biesiada J; Rance M; Thapa MB; Shah NP; Meller J; Zheng Y; Azam M
Sci Rep; 2015 Sep; 5():14538. PubMed ID: 26419724
[TBL] [Abstract][Full Text] [Related]
2. Structural Insights into JAK2 Inhibition by Ruxolitinib, Fedratinib, and Derivatives Thereof.
Davis RR; Li B; Yun SY; Chan A; Nareddy P; Gunawan S; Ayaz M; Lawrence HR; Reuther GW; Lawrence NJ; Schönbrunn E
J Med Chem; 2021 Feb; 64(4):2228-2241. PubMed ID: 33570945
[TBL] [Abstract][Full Text] [Related]
3. Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348).
Zhou T; Georgeon S; Moser R; Moore DJ; Caflisch A; Hantschel O
Leukemia; 2014 Feb; 28(2):404-7. PubMed ID: 23823659
[No Abstract] [Full Text] [Related]
4. Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect.
Choi J; Cooper ML; Alahmari B; Ritchey J; Collins L; Holt M; DiPersio JF
PLoS One; 2014; 9(10):e109799. PubMed ID: 25289677
[TBL] [Abstract][Full Text] [Related]
5. Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures.
Singer JW; Al-Fayoumi S; Taylor J; Velichko S; O'Mahony A
PLoS One; 2019; 14(9):e0222944. PubMed ID: 31560729
[TBL] [Abstract][Full Text] [Related]
6. Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms.
Deshpande A; Reddy MM; Schade GO; Ray A; Chowdary TK; Griffin JD; Sattler M
Leukemia; 2012 Apr; 26(4):708-15. PubMed ID: 21926964
[TBL] [Abstract][Full Text] [Related]
7. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.
Harrison CN; Schaap N; Vannucchi AM; Kiladjian JJ; Tiu RV; Zachee P; Jourdan E; Winton E; Silver RT; Schouten HC; Passamonti F; Zweegman S; Talpaz M; Lager J; Shun Z; Mesa RA
Lancet Haematol; 2017 Jul; 4(7):e317-e324. PubMed ID: 28602585
[TBL] [Abstract][Full Text] [Related]
8. Analogs of cinnamic acid benzyl amide as nonclassical inhibitors of activated JAK2 kinase.
Mielecki M; Milner-Krawczyk M; Grzelak K; Mielecki D; Krzysko KA; Lesyng B; Priebe W
Curr Cancer Drug Targets; 2014; 14(7):638-51. PubMed ID: 25146330
[TBL] [Abstract][Full Text] [Related]
9. How Does the L884P Mutation Confer Resistance to Type-II Inhibitors of JAK2 Kinase: A Comprehensive Molecular Modeling Study.
Kong X; Sun H; Pan P; Li D; Zhu F; Chang S; Xu L; Li Y; Hou T
Sci Rep; 2017 Aug; 7(1):9088. PubMed ID: 28831147
[TBL] [Abstract][Full Text] [Related]
10. Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling.
Gunby RH; Ahmed S; Sottocornola R; Gasser M; Redaelli S; Mologni L; Tartari CJ; Belloni V; Gambacorti-Passerini C; Scapozza L
J Med Chem; 2006 Sep; 49(19):5759-68. PubMed ID: 16970400
[TBL] [Abstract][Full Text] [Related]
11. Fedratinib: First Approval.
Blair HA
Drugs; 2019 Oct; 79(15):1719-1725. PubMed ID: 31571162
[TBL] [Abstract][Full Text] [Related]
12. A structure-function perspective of Jak2 mutations and implications for alternate drug design strategies: the road not taken.
Gnanasambandan K; Sayeski PP
Curr Med Chem; 2011; 18(30):4659-73. PubMed ID: 21864276
[TBL] [Abstract][Full Text] [Related]
13. Janus kinase 2 activation mechanisms revealed by analysis of suppressing mutations.
Hammarén HM; Virtanen AT; Abraham BG; Peussa H; Hubbard SR; Silvennoinen O
J Allergy Clin Immunol; 2019 Apr; 143(4):1549-1559.e6. PubMed ID: 30092288
[TBL] [Abstract][Full Text] [Related]
14. Understanding inhibitor resistance in Mps1 kinase through novel biophysical assays and structures.
Hiruma Y; Koch A; Hazraty N; Tsakou F; Medema RH; Joosten RP; Perrakis A
J Biol Chem; 2017 Sep; 292(35):14496-14504. PubMed ID: 28726638
[TBL] [Abstract][Full Text] [Related]
15. L1198F Mutation Resensitizes Crizotinib to ALK by Altering the Conformation of Inhibitor and ATP Binding Sites.
Li J; Sun R; Wu Y; Song M; Li J; Yang Q; Chen X; Bao J; Zhao Q
Int J Mol Sci; 2017 Feb; 18(3):. PubMed ID: 28245558
[TBL] [Abstract][Full Text] [Related]
16. Discovery of novel selective Janus kinase 2 (JAK2) inhibitors bearing a 1H-pyrazolo[3,4-d]pyrimidin-4-amino scaffold.
Yin Y; Chen CJ; Yu RN; Shu L; Zhang TT; Zhang DY
Bioorg Med Chem; 2019 Apr; 27(8):1562-1576. PubMed ID: 30846405
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Janus kinases by tyrosine phosphorylation inhibitor, Tyrphostin AG-490.
Rashid S; Bibi N; Parveen Z; Shafique S
J Biomol Struct Dyn; 2015; 33(11):2368-79. PubMed ID: 26017266
[TBL] [Abstract][Full Text] [Related]
18. The discovery of reverse tricyclic pyridone JAK2 inhibitors. Part 2: lead optimization.
Siu T; Kumarasinghe SE; Altman MD; Katcher M; Northrup A; White C; Rosenstein C; Mathur A; Xu L; Chan G; Bachman E; Bouthillette M; Dinsmore CJ; Marshall CG; Young JR
Bioorg Med Chem Lett; 2014 Mar; 24(6):1466-71. PubMed ID: 24582987
[TBL] [Abstract][Full Text] [Related]
19. Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F.
Bandaranayake RM; Ungureanu D; Shan Y; Shaw DE; Silvennoinen O; Hubbard SR
Nat Struct Mol Biol; 2012 Aug; 19(8):754-9. PubMed ID: 22820988
[TBL] [Abstract][Full Text] [Related]
20. Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells.
Okabe S; Tauchi T; Katagiri S; Tanaka Y; Ohyashiki K
J Hematol Oncol; 2014 Apr; 7():37. PubMed ID: 24775308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]